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Our understanding of the molecular mechanisms of T cell allo-
reactivity remains limitedby the lackof systems forwhichboth the
Tcell receptorallo-andcognate ligandareknown.Hereweprovide
evidence that a single alloreactive T cell receptor interacts with
analogous structural regions of its cognate ligand, HLA-
B*0801FLRGRAYGL, as its allogeneic ligand,HLA-B*3501KPIVVLHGY.
The crystal structures of the binary peptide-major histocompati-
bility complexes show marked differences in the conformation of
the heavy chains as well as the bound peptides. Nevertheless, both
epitopes possess a prominent solvent-exposed aromatic residue at
position 7 flanked by a small glycine at position 8 of the peptide
determinant. Moreover, regions of close structural homology
between the heavy chains ofHLAB8 andHLAB35 coincidedwith
regions thathavepreviouslybeen implicated in“hot spots”ofTcell
receptor recognition.The avidity of this humanTcell receptorwas
also comparable for the allo- and cognate ligand, consistent with
themodesofTcell receptorbindingbeingbroadly similar for these
complexes. Collectively, it appears that highly focused structural
mimicry against a diverse structural background provides a basis
for the observed alloreactivity in this system. This cross-reactivity
underpins the T cell degeneracy inherent in the limited mature T
cell repertoire that must respond to a vast diversity of microbial
antigens.
T cell receptors (TCRs)7 recognize antigens bound to major
histocompatibility complex (MHC)molecules on the surface
of antigen-presenting cells. This interaction is genetically
restricted, occurring only between T cells and antigen-present-
ing cells originating from a syngeneic background, giving rise to
the concept of “MHC restriction” (1). Despite the limitations
imposed byMHC restriction, a large number of TCRs are reac-
tive with “non-self ” or allogeneic MHC molecules, with some
studies estimating alloreactive T cell frequencies of up to 10%
(2). Direct T cell alloreactivity contributes significantly to com-
plications associated with organ transplantation and is a long-
standing paradox in cellular immunity. In a clinical context, T
cell allorecognition manifests as graft versus host disease in
bone marrow transplantation or graft rejection in solid organ
transplantation. Despite advances made using immunosup-
pressive agents, both graft versus host disease and organ rejec-
tion are still associated with a high degree of morbidity and
mortality. Thus, a better understanding of the mechanism of T
cell alloreactivity is needed to further advance post transplant
therapeutics.
Various attempts to explain the molecular interactions that
lead to TCR alloreactivity have resulted in two main schools of
thought.Onemodel proposes that the alloreactiveTCRdirectly
recognizes polymorphisms in the allo-MHC molecules inde-
pendent of the bound peptide, giving rise to a high “antigen
density” (3). Alternatively, if the TCR perceives the similari-
ties of the foreign MHC molecule and focuses on one or
more of the diverse peptides that appear foreign when pre-
sented by allogeneic MHC molecules, this constitutes a
“determinant frequency” alloresponse. In this second model,
it is argued that the many thousands of “foreign” peptides
would create at least one determinant for cross-reactive rec-
ognition by the TCR (4). The latter model includes T cell
responses to peptides that differ in sequence as well as
responses to the same peptide adopting different conforma-
tions when bound by the allo and self MHC molecules.
Examples of alloresponses demonstrating a range of peptide
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dependence have been documented from T cells recognizing
alloantigens in a more “peptide-independent” manner (5–7)
to alloresponses that are peptide-dependent (8–14). The
spectrum of peptide-dependent (and specific) alloresponses is
considered to vary according to the level of similarities between
the self-MHC and allo-MHC molecules, with increased pep-
tide-specific responses observed with increased similarities
(15).
Understanding the molecular and structural basis of T cell
alloreactivity has been limited by the lack of available systems
for which the sequences of the TCR, syngeneic ligand, and allo-
geneic ligands are all known. The crystal structures have been
determined for the 2C-H2-Kbm3/H2-Kb system (8), demon-
strating a shared dockingmode of the 2CTCR on the alloligand
and the syngeneic ligand. In this system, the sequence of the
alloligand peptide is identical to the cognate peptide, and the
H2-Kbm3 and H2-Kb molecules differ by only two amino acids.
Another study compared the crystal structures of BM3.3 TCR
in complex with H-2Kb presenting either the VSV8 octamer
peptide or the naturally processed peptide, pBMI (16). These
systems have given some insight into TCR cross-reactivity but
have limitations as they have either identical peptides or iden-
ticalMHCmolecules. As such, theymay not adequately explain
allorecognition involving very disparate MHC class I allotypes
and alloligand peptides of differing amino acid sequence(s).
We chose to study an alloreactive humanTcell clone, termed
JL9, that recognizes the peptide FLRGRAYGL (referred to as
FLR), an immunodominant epitope derived from the latent
Epstein-Barr virus (EBV) nuclear antigen 3A (EBNA3A), bound
toHLA-B*0801 (17, 18). The JL9 cytotoxic T lymphocyte (CTL)
clonewas alloreactive againstHLA-B*3501, as demonstrated by
lysis of HLA-B*3501-expressing target cells in the presence of a
peptide derived from human cytochrome P450, KPIVVLHGY
(referred to as KPI) (18). In this system there is little similarity
between the cognate and allopeptide, and HLA-B*3501 differs
fromHLA-B*0801 by 19 amino acids. The basis for the JL9TCR
alloreactivity was examined by avidity measurements, peptide
substitution studies, and x-ray crystallography. Our data are
consistent with T cell allorecognition being dependent on
highly focused structural mimicry between the disparate cog-
nate and allogeneic allotypes.
EXPERIMENTAL PROCEDURES
Flow Cytometric Analysis—T cell clones or peripheral blood
mononuclear cells were incubated for 30 min at 4 °C with a
PE-labeled HLA-B*0801FLR pentamer and/or an antigen-pre-
senting cell-labeled HLA-B*3501KPI pentamer (ProImmune).
Cells were then washed twice in FACS buffer (1% fetal calf
serum in PBS) and labeled for 30 min at 4 °C with Tri-color-
labeled anti-human CD8monoclonal antibody (Caltag Labora-
tories). The cells were then washed with FACS buffer, fixed
with Cytofix (BD Biosciences), and analyzed on a FACSCanto
using FACSDiva software (BD Biosciences). For the pentamer
dilution analysis, T cell clones (2 107 cells/ml)were incubated
with increasingdilutionsofpentamer (1:100–1:51200) in100l of
FACSbuffer for 30minat 4 °C.Thecellswere thenwashed3 times
with FACS buffer, fixed, and analyzed as described above.
T Cell Cytotoxicity Assays—CTL clones were tested in dupli-
cate in the standard 5-h chromium release assay for cytotoxicity
against 51Cr-labeled target cells that had been treated for 1 h
with various concentrations of peptide. The target cells were
HLA-B*0801 or HLA-B*3501 phytohemagglutinin blasts
that were raised by stimulating peripheral blood mononuclear
cells with phytohemagglutinin followed by propagation in
interleukin-2-containing medium for up to 8 weeks. Target
cells were added to effector cells at a ratio of 1:1. Percent spe-
cific lysis was calculated, and the peptide concentration
required for half-maximum lysis was determined from dose-
response curves. Peptides were synthesized byMimotopes. A 
scintillation counter (Topcount Microplate; Packard Instru-
ment Co.) was used to measure 51Cr levels in assay supernatant
samples. The mean spontaneous lysis for targets in culture
medium was always 20%, and variation about the mean spe-
cific lysis was10%.
Expression, Purification, and Crystallization of HLA B*3501—
Soluble HLA-B*3501 molecules (residues 1–276) and full-
length 2-microglobulin (residues 1–99) were expressed,
refolded with the KPIVVLHGY peptide, purified, and concen-
trated to 10 mg/ml as previously described (19). The HLA-
B*3501KPI crystals were obtained by the hanging drop vapor
diffusionmethod. Block-shaped crystals grew within 10 days in
conditions containing 0.2 M ammonium acetate and 18% w/v
polyethylene glycol 3350 (100 mM cacodylate, pH 7.6) at 4 °C.
X-ray Data Collection and Structure Determination—Crys-
tals were soaked in reservoir solution containing increasing
increments of glycerol as a cryoprotectant (5, 10, 15, and 20%)
and then flash-frozen before data collection. Data were col-
lected on an in-house radiation source (a Rikagu RU-3HBR
rotating anode generator) and processed and scaled using the
HKL suite (20).The HLA-B*3501KPI structure was refined from
a HLA-B*3501 structure that was previously determined in our
laboratory.8 The model was manually built using the program
O (21) and improved through multiple rounds of refinement
using the CNS suite (22). The progress of refinement was mon-
itored by the Rfactor and the Rfree values. Rigid body refinement
and simulated annealing were used in the first instance, and
later rounds of energy minimization and B-individual refine-
ment were used to improve the quality of the model. After this,
more rounds of refinement were implemented using the REF-
MAC (23) program and subsequentmodel building usingWin-
Coot (24).Watermolecules were included if they had a B-factor
less than 60Å2, appeared inFoFcmaps contoured at 3.5 and
were within hydrogen-bonding distance to chemically reason-
able groups. See Table 1 for the final refinement and model
statistics. The structure has been deposited in the Protein Data
Bank under code 2H6P.
RESULTS
Cross-reactivity of an HLA-B8/EBV-reactive T Cell Clone
with theAlloantigenHLA-B*3501KPIVVLHGY—HLA-B*0801-re-
stricted T cell clones specific for the EBV epitope FLRGRAYGL
isolated from unrelated HLA-B8, B44 individuals have pre-
8 N. A. Borg, F. E. Tynan, J. J. Miles, D. El-Hassen, S. L. McCluskey, S. R. Burrows,
and J. Rossjohn, unpublished information.
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viously been shown to alloreact with HLA-B*3501-expressing
cells (18). To investigate the mechanism of T cell alloreactivity,
the binding specificities of a representative EBV/allo-cross-re-
active T cell clone (called JL9) were first investigated. MHC
pentamers of the cognate viral ligand HLA-B*0801FLR and the
alloligand HLA-B*3501KPI were used to co-stain the CD8 JL9
T cell clone (Fig. 1A). The JL9 T cells recognized the alloligand
and the cognate viral ligand with the same level of specificity
because both pentamers were able to specifically react with the
JL9 clone simultaneously andwith very similar levels of fluores-
cence intensity. As controls, the same pentamers were used to
stain the FLR-specific, HLA-B*0801-restricted CTL clone
LC13, which is not alloreactive withHLA-B*3501 (17) (Fig. 1B),
and the ELS4 CTL clone, which is specific for another EBV
epitope and is not alloreactive (25) (Fig. 1C).
To determine whether T cells with this dual specificity can
be detected ex vivo, peripheral blood mononuclear cells were
isolated from two EBV-seropositive, HLA-B*0801,
B*4402 donors and tested for their ability to bind HLA-
B*0801FLR and HLA-B*3501KPI. A small but detectable pop-
ulation of HLA-B*3501KPI allospecific T cells (0.2% of CD8
cells) was observed directly ex vivo in both donors (supple-
mental Fig. 1). Donors with the HLA-B8, B44 phenotype
typically have a low frequency of HLA-B*0801FLR specific
memory T cells ex vivo (26).
T Cell Avidity and Affinity—Fluorescently labeled, soluble
MHC multimers can detect differences in avidities of MHC-
specific T cells using flow cytometry (27–30).WhenMHCmul-
timers are used as a limiting reagent, only high avidity T cells
bind the multimers, while using the multimers at saturating
levels identifies both low and high avidity T cells. To determine
whether there is a difference in T cell avidity for an alloligand
compared with a syngeneic ligand, the alloreactive T cell clone
JL9 was stained with limiting dilutions of pentamers of the
alloligand HLA-B*3501KPI and the syngeneic ligand HLA-
B*0801FLR. The JL9 T cell clone was stained over a range of
pentamer dilutions from 1:100 to 1:51,200 (Fig. 2). The staining
profile for the two pentamers followed the same trend at each
dilution, with the limiting point at which pentamer binding
ceased being observed at the 1:6400 dilution for both the allo
pentamer and the cognate pentamer. Consistent with data
shown in Fig. 1B, the control LC13 CTL clone stained only with
theHLA-B*0801FLR pentamer. These results reveal that the JL9
TCR shows no significant difference in avidity for the allo
ligand compared with the cognate ligand.
Fine Peptide Specificity Analysis of the Alloreactive TCR—To
investigate how the single TCR expressed by the JL9 CTL clone
binds with similar avidity to these two disparate target ligands,
we conducted a fine peptide specificity analysis using altered
peptide ligands presented in the context of either HLA-B*0801
or HLA-B*3501. An earlier study that examined the fine speci-
ficity of this CTL clonotype by testing for recognition of ana-
logues of the FLR peptide at a single peptide concentration
identified positions 6–8 as the likely TCR contact residues (18).
The JL9 CTLs were, therefore, tested for their ability to tolerate
single amino acid substitutions at positions 6, 7, and 8 within
the FLR and KPI peptides. A total of 57 single amino acid-
substituted analogues of both the FLR and KPI peptides were
tested for CTL recognition using peptide dose-response cyto-
toxicity assays with phytohemagglutinin blast target cells
expressing either HLA-B*0801 (Fig. 3A) or HLA-B*3501 (Fig.
FIGURE 1. JL 9 CTL cross-reactivity. FACS analysis of CTL clones co-stained
with both a PE-labeled HLA-B*0801FLR pentamer (y axis) and a antigen-pre-
senting cell-labeled HLA-B*3501KPI pentamer (x axis) in a single tube. A, the
JL9 clone, previously found to cross-recognize both HLA-B*0801FLR and the
alloligand HLA-B*3501KPI in cytotoxicity assays (18), bound both pentamers
simultaneously. B, the LC13 clone, previously found to recognize only the
HLA-B*0801FLR complex in cytotoxicity assays (18), bound only the HLA-
B*0801FLR pentamer. C, the ELS4 clone, which recognizes the unrelated
EPLPQGQLTAY-HLA-B*3501 complex, was used as a negative control. Like-
wise, neither the HLA-B*0801FLR or HLA-B*3501KPI pentamers bound to ELS4.
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3B), and the concentration of peptide required for half-maxi-
mum lysis was determined.
Although the total number of peptide amino acid substitu-
tions that prevented lysis by JL9 was greater for the HLA-
B*3501KPI target ligand than for the HLA-B*0801FLR complex,
the total number of peptide amino acid substitutions that led to
a 10-fold loss of lytic activity was very similar for the two
complexes. The JL9 CTL clone was more sensitive to substitu-
tions at position 6 in the HLA-B*3501KPI complex in compari-
son to the HLA-B*0801FLR complex, which may reflect differ-
ential roles for position 6 inMHC binding, since the Leu at this
position points in toward theMHC cleft in the HLA-B*3501KPI
complex, whereas the Ala at position 6 is a solvent-accessible
residue in the HLA-B*0801FLR complex (see below). The small
Gly residue at position 8 was critical for recognition of both
complexes. Furthermore, the JL9 CTL clone displayed a prefer-
ence for an aromatic side chain at position 7 within each com-
plex, indicating that this is an important TCR contact residue in
both complexes.
Crystal Structure of the HLA-B*3501KPIVVLHGY Complex—
The crystal structure of HLA-B*3501KPI was determined to 1.9
Å and to an Rfactor of 21% and an Rfree of 23.1% (Table 1). The
electron density of the bound peptide KPIVVLHGY and the
residues contacting it in HLA-B*3501 was unambiguous, pro-
viding a clear view of the allogeneic pMHC landscape (Fig. 4).
The HLA heavy chain (residues 1–276) and -2-microglobulin
(residues 1–99) adopted the expected MHC class I and immu-
noglobulin-like folds, respectively (31). The peptide, which
bound in an extended conformationwithin the antigen-binding
cleft, was observed to exhibit limited flexibility (Fig. 4), with all
residues possessing similar B-factors (ranging from 29 to 34
Å2). Consequently, the KPI peptide participates in numerous
van der Waals interactions, 12 direct H-bonds, and 4 water-
mediated H-bonds with the heavy chain (Table 2). The anchor
residues for peptide binding toHLA-B*3501 are located at posi-
tions 2 and 9. The P2-Pro and P9-Tyr were observed to make
the standard anchor contacts in the B- and F-pockets, respec-
tively, withinHLA-B*3501 (25, 32–34). The P3 andP6positions
also display limited solvent accessibility, with the hydrophobic
P3-Ile and P6-Leu pointing into, and making numerous con-
tacts with the antigen binding cleft. The solvent-exposed resi-
dues of the peptide are P1-Lys, P4-Val, P5-Val, and P7-His, with
solvent exposure values of 49, 65, 42, and 91 Å2, respectively;
accordingly the most prominent P7-His residue appears to be
an important contact point for the JL9 TCR.
Comparison of the Cognate and Allogeneic Complexes—
Given that the JL9 T cell clone lyses both HLA-B*3501KPI and
B*0801FLR, expressing cells with comparable efficiency and
binds to pentamers of both ligands with equal avidity, the over-
all structures of these two pMHC complexes were compared to
better understand the structural basis of allorecognition. HLA-
B*3501 and HLA-B*0801 differ by 19 amino acids, with most of
the differences residingwithin the peptide binding cleft and not
directly accessible to the JL9 TCR (Fig. 5). Of the polymorphic
residues, two positions (97 and 116) participate in peptide bind-
ing (Fig. 5), and two positions (131 and 163) map to the anti-
FIGURE 2. T cell avidity of the LC13 and JL9 T cell clones. Both T cell clones were stained with a series of dilutions of pentamers of HLA-B*0801FLR and
HLA-B*3501KPI at concentrations ranging from1:100 to 1:51,200. The LC13 CTL only stainswith theHLAB*0801 pentamer. The JL9 CTL showed a similar avidity
for both the HLA-B*0801FLR and the HLA-B*3501KPI pentamers.
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genic surface (Fig. 6, A and B). Three of the polymorphic posi-
tions, 156 (Asp3Leu), 163 (Thr3Leu), and 194 (Ile3Val)
superpose poorly, with rootmean square deviation (r.m.s.d.) for
these positions of 1.23, 1.04, and 1.38 Å, respectively. Overall,
the antigen binding clefts of HLA-B*3501 and HLA-B*0801
superposed relatively poorly, with an overall r.m.s.d. of 0.85 Å.
Considering that the JL9 TCR interacts with both of these
peptide concentration required for half-maximal lysis by the JL9 CTL clone is
shown for the various peptide analogs. The amino acid substitutions are
shownon the vertical axis, and the logmolar concentration of peptide analog
is shown on the horizontal axis. The effector/target ratio employed for the
replacement assay was 1:1.
FIGURE 3. Peptide repertoire for the JL9 CTL. Amino acid substitution
experiments depict how well the JL9 CTL clone tolerates amino acid
changes at positions 6, 7, and 8 within FLR (A) versus KPI (B). The log
TABLE 1
Crystallographic statistics for HLA-B*3501KPIVVLHGY
Values in parentheses are for the highest resolution shell.
Data collection
Temperature 100 K
Space group P212121
Cell dimensions (Å) (a, b, c) 51.22, 82.01, 110.26
Resolution (Å) 1.9
Total number of observations 180277
Number of unique observations 36,699
Multiplicity 4.91
Data completeness (%) 98.1 (83.6)
No. data2I (%) 81.8 (41.3)
I/I 20.7 (2.15)
Rmergea (%) 9.1 (54.8)
Model refinement
Non-hydrogen atoms
Protein 3,156
Water 401
Resolution (Å) 66-1.9
Rfactorb (%) 21.0
Rfreec (%) 23.9
r.m.s.d. from ideality
Bond lengths (Å) 0.006
Bond angles (°) 1.27
Dihedrals (°) 24.99
Impropers (°) 0.807
Ramachandran plot
Most favored region 91.9
Allowed region (%) 8.1
B-factors (Å2)
Average main chain 33.55
Average side chain and water molecules 36.07
r.m.s.d.-bonded B-factors 1.24
aRmerge Ihkl Ihkl	/Ihkl.
bRfactorhklFo Fc/hklFo.
c Rfree 5% of the data used for this calculation.
FIGURE 4. Structure of the allogeneic stimulating peptide, KPI, com-
plexed to the MHC. The cytochrome P450 derived peptide, KPIVVLHGY
(aqua), sitting in the peptide binding cleft of the MHC, HLA-B*3501 (green).
The surrounding final 2Fo  Fc electron density for the peptide is shown in
mesh format. This figure shows thepositions of key anchor residues (Pro2 and
Tyr9) and possible TCR contact residues (Val4, Val5, and His7).
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pMHC complexes, it is interesting to note that the overlay of
the 1 and 2 helices and bound peptide reveal marked differ-
ences (Fig. 6C), with r.m.s.d. values of1 Å for region 70–77 of
the 1 helix and 141–152,156–159, 162–163 for the 2 helix.
The conformation of the two peptides within their respective
antigen binding clefts, excluding positions 7–9, are markedly
different (Fig. 6C), with an overall r.m.s.d. of 1.35 Å. The P7 to
P8 region of the two peptides adopt themost similar conforma-
tion, with an r.m.s.d. of 0.18 and 0.20 Å for each C, respec-
tively. The peptide substitution data for the JL9 CTLs revealed
a shared fine specificity at P7 and P8 for both the cognate and
allo target peptides. Both HLA-B*0801FLR and HLA-B*3501KPI
share the feature of a bulky, highly solvent exposed aromatic
residue at P7 that protrudes out of the cleft (Tyr7 in FLR andHis
7 in KPI); this position was shown to be critical for JL9 TCR
recognition. Interestingly, the JL9 CTL clone displayed a strin-
gent requirement for a glycine at P8 for cytolytic activity, which
suggests that it is important for the JL9TCR to formmain chain
interactions with P8 and/or that a small residue is required to
allow optimal engagement of the bulky residue at P7 by the JL9
TCR. These requirements at P7 and P8 for recognition by the
JL9 TCR are comparable with those observed for recognition of
HLA-B*0801FLR by an immunodominant TCR called LC13
(35). Like the JL9 clone, the LC13CTL clone ismost sensitive to
substitutions at the C-terminal end of the FLR peptide, as dem-
onstrated by single amino acid substitution experiments (18,
35). Correspondingly, the peptide substitution experiment for
the KPI peptide in the current study suggests that the JL9 TCR
has a similar C-terminal based footprint on the alloligandHLA-
B*3501KPI (Fig. 6C).
DISCUSSION
In unrelated HLA-B*0801 individuals, the CD8 T cell
response toward the EBV latent epitope FLRGRAYGL is char-
acterized by use of an immunodominant TCR, termed LC13
(36). Single amino acid substitution experiments of the FLR
peptide bound to HLA-B*0801 revealed that the LC13 CTL
clone was very sensitive to substitutions toward the C terminus
of the peptide, specifically the highly exposed P7-Tyr, and the
two small residues that flank this position (35). The crystal
structure of the LC13-HLA-B*0801FLR complex provided a
basis for this specificity whereby the P7-Tyr was enveloped
within a centrally located pocket of the LC13 TCR, with the
P6-Ala and P8-Gly forming main chain hydrogen bonds to the
LC13 TCR (35, 37). To optimally engage the P7-Tyr of the FLR
epitope, the LC13 TCR was observed to dock diagonally and
adopt a C-terminal focused footprint onto HLA-B*0801FLR.
Interestingly, the LC13 TCR is alloreactive against HLA-
B*4402, and in HLA-B8B44 heterozygous individuals the
LC13 TCR is deleted from the repertoire, presumably as a con-
sequence of negative selection during thymic development (26,
38). In these individuals, T cells expressing alternative TCRs are
selected to interact with HLA-B*0801FLR, including the JL9
CTL clone. The JL9 T cell clone is another example of an HLA-
B*0801FLR-specific clonotype that uses identical TCR chains
TABLE 2
Interactions between KPIVVLHGY and HLA B*3501
Peptide residue HLA-B35 residues Interaction
Lys1
Lys Tyr7, Arg62, Tyr159, Trp167,
Tyr171
Van der Waals
LysN Tyr7 OH H-bond
Tyr171 OH H-bond
LysO Tyr171 OH H-bond
Tyr159 OH H-bond
LysNZ Trp167 N1 Water-mediated
H-bond
Pro2
Pro Tyr7, Tyr9, Phe67, Asn63,
Tyr99, Tyr159
Van der Waals
ProN Tyr7 OH H-bond
Ile3
Ile Ile66, Tyr99, Gln155, Tyr159 Van der Waals
IleN Tyr99 OH H-bond
Val4
Val Arg62, Ile66 Van der Waals
Val5
Val Ile66, Thr69, Asn70, Thr73 Van der Waals
ValO Gln155 O1 Water-mediated
H-bond
Leu6
Leu Thr73, Arg97, Gln155,
Leu156
Van der Waals
LeuO Asn70 O1 Water-mediated
H-bond
His7
His Ala150, Trp147 Van der Waals
HisO Arg97 NH1 Water-mediated
H-bond
Gly8
Gly Thr73, Ser77, Trp147 Van der Waals
GlyO Trp147 N1 H-bond
Tyr9
Tyr Tyr74, Ser77, Asn80, Leu81,
Tyr84, Ile95, Arg97,
Ser116, Tyr123, Thr 143,
Lys146, Trp147
Van der Waals
Ser77 O H-bond
TyrN Ser116 O H-bond
TyrOH Asn80 O1 H-bond
TyrO Lys146 NZ H-bond
TyrOXT Tyr84 OH H-bond
Thr143 O1 H-bond
FIGURE 5. Polymorphisms between HLA-B*3501 and HLA-B*0801. This
figure shows a top view of the MHC molecule, highlighting the polymorphic
residues between HLA-B*3501 and HLA-B*0801 as would be seen by a T cell
receptor. The HLA-B*0801 residue is listed first, followed by the residue num-
ber and the corresponding HLA-B*3501 residue. The polymorphic residues
that are involved with binding of the KPI peptide to HLA-B*3501 are colored
in red; all other polymorphic residues are colored in yellow.
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(TRAV1-2*01, TRAJ36*01, and TRBV4-3*01, TRBJ2-5*01,
TRBD2*02) that are found in unrelated individuals. The JL9
TCR is also known to be alloreactive against a peptide derived
from cytochrome P450, KPIVVLHGY, in the context of HLA-
B*3501 (18).
In this report we have determined the crystal structure of the
allogeneic pMHC complex HLA-B*3501KPI and compared it to
the previously determined structure of the JL9 cognate ligand
HLA-B*0801FLR (39). A comparison of these crystal structures
combined with functional data for the alloreactive T cell clone
JL9 has provided insight into the structural mechanism of the
alloreactive T cell response. In the flow cytometry experiments,
both the HLA-B*3501KPI and HLA-B*0801FLR pentamers pos-
itively stained the JL9T cell clone, demonstrating the structural
plasticity of the JL9 TCR. Moreover, the JL9 clone reacted with
similar avidity to the HLA-B*3501KPI and the HLA-B*0801FLR
pentamers. Early studies suggested that TCRs had a much
higher affinity for alloligands compared with syngeneic ligands
(40, 41). Although additional studies have demonstrated a sim-
ilarity in the functional avidity of a TCR for an allogeneic and
syngeneic ligand (42), the small number of cases for which both
an allogeneic and cognate ligand are known for a particular
TCR limits the availability of affinity data. Interestingly, the
affinity of the well studied alloreactive 2C TCR differs accord-
ing to the type of allogeneic ligand it recognizes (43). Our pres-
ent study represents the first report of a TCR reacting with
comparable avidities for an alloligand and a cognate ligand.
The peptide substitution data revealed that the JL9 TCR was
exquisitely sensitive to amino acid replacement at positions 7
and 8 of the cognate peptide, analogous to that exhibited by the
LC13TCR (35), suggesting that the JL9TCR also forms aC-ter-
minal footprint on HLA-B*0801. Moreover, the JL9 TCR was
sensitive to substitutions at positions 7 and 8 of the allopeptide
(P7-His, P8-Gly), which is consistent with the requirement for
an aromatic residue at position 7, and a flanking glycine residue.
This observation is also consistent with the JL9 TCR having a
C-terminal biased footprint on the alloligand HLA-B*3501KPI
that is similar to the cognate HLA-B*0801FLR complex.
Although the allogeneic and cognate peptide differedmarkedly
in sequence and in the overall conformation within their
respective antigen binding clefts, they were observed to possess
structural similarity and adopt a homologous conformation at
positions 7 and 8. The localized bulge at P7 in the KPI peptide
(P7-His) and the FLR peptide (P7-Tyr) provides a conserved
prominent feature that is likely to form similar interactions
with the JL9 TCR, possibly in an analogous mode observed for
LC13 binding to the FLR peptide (35).
As with most TCR/pMHC complexes, the JL9 TCR will also
make extensive contacts with the MHC heavy chain. In this
regard, it was of interest to observe that the antigen-binding
cleft of HLA-B*0801 and HLA-B*3501 did not overlay closely.
This was somewhat surprising, given that patterns of alloreac-
tivity can be dictated by single amino acid changes that confer
subtle structural differences within the -helices of the binding
cleft. For example, the single amino acid disparity between the
HLA-B*4402 and HLA-B*4403 results in graft rejection and
graft versus host disease when the donor and recipient are mis-
matched for these alleles (44, 45), defining them as a “taboo
mismatch” in tissue transplantation. HLA-B*0801 and HLA-
B*3501 differ by 19 amino acids, and the majority of these dif-
ferences are not directly accessible by the JL9 TCR. Neverthe-
FIGURE 6. Highly focused molecular mimicry between the allo- and cog-
nate ligands explains JL9 cross-reactivity. Surface representation of (self-
HLA-B*0801FLR (A) and allo-HLA-B*3501KPI (B). The surface of HLA-B*0801FLR
and HLA-B*3501KPI differ, especially around the peptides and their binding
clefts. The polymorphic residues are colored in orange, the FLRGRAYGL pep-
tide is colored in pink, and the KPIVVLHGY peptide is colored in aqua. For the
polymorphic residues, the HLA-B*0801 residue is listed first followed by the
residue number and then the corresponding HLA-B*3501 residue. The ener-
getic hot spot residues for recognition of HLA-B*0801FLR by the LC13 TCR are
also shown (yellow). C, overlay of the 1 and 2 helices of HLA-B*0801 (blue)
and HLA-B*3501 (green). The FLR peptide is colored in pink, and the KPI pep-
tide is colored in aqua. The CDR loops of the LC13 TCR are shown in orange.
The MHC residue positions known to be important for LC13 recognition of
HLA-B*0801FLR are highlighted in yellow. In particular, the three residues of
the restriction triad at positions 65, 69, and 155 appear to be conserved
structurally.
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less, buried polymorphic residues are known to impact on TCR
recognition via changes in the local conformation of the -hel-
ices or peptide binding specificity and conformation. The over-
all structural disparity between HLA B*3501 and HLA B*0801
suggests that either JL9 docks differently between these two
pMHC complexes or that the JL9 TCR fortuitously interacts
with the regions of structural similarity. Although the MHC
typically makes extensive contacts with the TCR, alanine-scan-
ning mutagenesis has revealed that only a few MHC residues
are critical for engagement (46, 47). The concept of an “ener-
getic hot spot” of recognition was reinforced by the recent
structure determination of a “super-bulged” TCR-pMHC com-
plex, where the TCR was observed to make minimal contacts
with the MHC heavy chain (48). Of interest, this TCR only
made two contact points on the 1 helix (positions 65 and 69)
and a small and focused number of contacts on the 2 helix
(spanning residues 150–163). Comparative analysis of known
TCR-pMHC structures indicated that the residues at positions
65, 69 on the 1 helix, and residue 155 on the 2 helix, repre-
sented a “restriction triad,” providing a minimal generic foot-
print for MHC restriction (48). Interestingly, in the allogeneic
and cognate pMHCcomplexeswe describe here, the conforma-
tion of the triad of residues are conserved structurally (Fig. 6C).
Thus, highly focusedmolecularmimicry in both theC-terminal
region of the peptide and theMHC restriction triad of residues
provides a plausible explanation for how the JL9 TCR may be
able to interact with two such structurally different pMHCs.
The cross-reactivity of TCRs was recently examined in a
study on the BM3.3 TCR. These experiments showed that
the rearrangements of the complementarity-determining
region (CDR) 3 provide an explanation for the inherent
cross-reactivity of the TCR (16). For this system, the two
MHC molecules are identical, and the authors describe how
a single TCR may be able to accommodate peptide variants.
Here, the CDR3 loop moves to accommodate changes in
the peptide, and as such, the authors propose that it is not
molecular mimicry of the peptide but CDR3 loop rearrange-
ment that explains how TCRs may adapt to structurally dif-
ferent peptides. Despite the CDR3 loop rearrangement, the
BM3.3 TCR CDR loops focus on regions of structural simi-
larity between the two pMHC ligands (a similar region of the
peptide, and regions on the 1 and 2 helices), thus also
displaying a degree of focused mimicry.
Molecularmimicry has previously been observed in the cross
recognition of an EBV antigen by an autoreactive class II
restricted TCR (49). Here the two pMHC ligands are structur-
ally similar, and four TCR-peptide contacts are conserved. The
authors hypothesize that structural mimicry of the TCR recog-
nition surface forms a basis for TCR cross-reactivity. The dual
specificity of the JL9 TCR for two vastly different peptides and
MHC allotypes is another example of such structural mimicry,
and as such, JL9 alloreactivity is consistent with a “determinant
frequency” alloresponse.
T cells must be able to recognize a vast array of pathogens to
provide adequate protection for a host. To cover such an
immense number, it is inevitable that TCRs must “wear many
hats”; as such, alloreactivity is the price that is paid.
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11
Fig. 6.  Highly focused molecular mimicry between the allo- and cognate ligands explains JL9
cross-reactivity.  Surface representation of (A) self-HLA-B*0801FLR and (B) allo-HLA-B*3501KPI.
The surface of HLA-B*0801FLR and HLA-B*3501KPI differ, especially around the peptides and their
binding clefts.  The polymorphic residues are colored in orange, the FLRGRAYGL peptide is colored
in pink and the KPIVVLHGY peptide is colored in aqua.  For the polymorphic residues, the HLA-
B*0801 residue is listed first, followed by the residue number and then the corresponding HLA-
B*3501 residue.  The ‘energetic hot spot’ residues for recognition of HLA-B*0801FLR by the LC13
TCR are also shown (yellow).  (C) Overlay of the 1 and 2 helices of HLA-B*0801 (blue) and
HLA-B*3501 (green).  The FLR peptide is colored in pink and the KPI peptide is colored in aqua.
The complimentarity-determining regions (CDR) loops of the LC13 TCR are shown in orange.  The
MHC residue positions known to be important for LC13 recognition of HLA-B*0801FLR are
highlighted in yellow.  In particular, the three residues of the ‘restriction triad’ at positions 65, 69 and
155 appear to be conserved structurally.
Supplementary Fig. 1. FACS analysis of peptide-stimulated bulk cultures co-stained with both a PE-
labeled HLA-B*0801FLR pentamer (Y axis) and a APC-labeled HLA-B*3501KPI pentamer (X axis) in
a single tube. Dual staining of PBMC from two EBV-seropositive donors with pentamers revealed a
pentamer frequency of 0.2% of CD8 positive cells ex vivo.  Cells were stimulated and expanded in
vitro and used for dual staining with both pentamers. (A) PBMC from EBV-seropositive donor KK
(HLA-B*0801+, HLA-B*4402+) were stimulated with the FLR peptide in vitro and the subsequent
bulk culture was analysed for HLA-B*3501KPI cross-reactivity on day 10. (B) Likewise, PBMC from
EBV-seropositive donor PM (HLA-B*0801+, HLA-B*4402+) were stimulated with the FLR peptide
in vitro and the subsequent bulk culture was analysed for HLA-B*3501KPI cross-reactivity on day 10.
(C) Donor EL (HLA-B*0801-, HLA-B*4402-) was used as a negative control. PBMC from EBV-
seropositive donor EL were stimulated with the unrelated peptide EPLPQGQLTAY in vitro and the
subsequent bulk culture was analysed with a PE-labeled HLA-B*3501EPLP pentamer and a HLA-
B*3501KPI pentamer to detect non-specific cross-reactivity on day 10. The figures in the upper right
quadrants indicate the percentage of total CD8+ pentamer+ cells.
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